You have full access to this article via your institution. Available treatments for COPD are mainly palliative, and there are no therapies available that halt the decline in lung function or the ...

The Spanish COPD guidelines recommend treatment of the mixed COPD ... acting muscarinic receptor antagonists (LAMA) to ICS + long-acting b2 agonist (LABA) combination for 'triple therapy'.

Further, if initial pharmacotherapy with LABA or LAMA after a COPD ... 1,8 Among treatment-related factors for nonadherence is the diversity of COPD pharmacotherapies and devices.

The goals of COPD treatment include reducing symptoms, preventing and treating exacerbations, reducing deaths related to the disease 3, and changing the underlying nature of the disease (otherwise ...

Current maintenance or controller treatments for COPD include tiotropoium, LAMA, LABA, LABA + ICS, LAMA + LABA, roflumilast, theophylline, and 'triple therapy' combining LAMA + LABA + ICS.

in COPD. As many patients on maintenance therapies take an ICS/LABA combination, and an additional puff on a LAMA inhaler, Trimbow will represent a more convenient therapy in the likely event of ...

In the CRYSTAL study, patients with moderate COPD who were switched to Ultibro Breezhaler from their previous therapy (LABA+ICS * or LABA or LAMA) experienced superior improvements in lung ...

The other single-inhaler on the market for COPD triple therapy, fluticasone-umeclidinium ... powder inhaler over a metered-dose inhaler of LABA-LAMA-inhaled corticosteroid in a single inhaler ...

Verona Pharma's Ohtuvayre, a novel COPD treatment, achieved $36 million in Q4 sales, indicating strong market interest and unmet need for new therapies. Despite aggressive pricing, Ohtuvayre's ...